Cargando…

Case report: PSMA PET/CT addresses the correct diagnosis in a patient with metastatic prostate cancer despite negative core biopsies and mpMRI. A diagnostic challenge

This is a case of [(68) Ga]Ga-Prostate-specific membrane antigen (PSMA)-11 PET/CT in a 73-years old patient presenting high Prostate Specific Antigen (PSA) levels despite both multi-parametric magnetic resonance imaging (mpMRI) and 12-core saturation biopsy negative for prostate cancer (Pca). This i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vetrone, Luigia, Cuzzani, Giulia, Mei, Riccardo, Zanoni, Lucia, Bertaccini, Alessandro, Bianchi, Lorenzo, Castellucci, Paolo, Gaudiano, Caterina, Cappelli, Alberta, Giunchi, Francesca, Fanti, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941543/ https://www.ncbi.nlm.nih.gov/pubmed/36824128 http://dx.doi.org/10.3389/fonc.2023.1101221

Ejemplares similares

Histology and PSMA Expression on Immunohistochemistry in High-Risk Prostate Cancer Patients: Comparison with (68)Ga-PSMA PET/CT Features in Primary Staging
por: Vetrone, Luigia, et al.
Publicado: (2023)

Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI
por: Laudicella, Riccardo, et al.
Publicado: (2022)

Role of mpMRI of the prostate in screening for prostate cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2017)

Analysis of the cause of missed diagnosis in mpMRI/TRUS fusion-guided targeted prostate biopsy
por: Zhang, Fan, et al.
Publicado: (2022)

The role of mpMRI in qualification of patients with ISUP 1 prostate cancer on biopsy to radical prostatectomy
por: Nyk, Łukasz, et al.
Publicado: (2021)

False-positive mpMRI and true-negative (68)Ga-PSMA PET/CT xanthogranulomatous prostatitis: a case report
por: Tang, Yongxiang, et al.
Publicado: (2022)

External validation of two mpMRI-risk calculators predicting risk of prostate cancer before biopsy
por: Pallauf, Maximilian, et al.
Publicado: (2022)

Mischievous malakoplakia: A potential pitfall of mpMRI of the prostate?
por: Rezaee, Michael E., et al.
Publicado: (2020)

Comparison of (68)Ga-PSMA-617 PET/CT with mpMRI for the detection of PCa in patients with a PSA level of 4–20 ng/ml before the initial biopsy
por: Li, Yu, et al.
Publicado: (2020)

Correlation between genomic index lesions and mpMRI and (68)Ga-PSMA-PET/CT imaging features in primary prostate cancer
por: Kesch, Claudia, et al.
Publicado: (2018)

Clash of the calculators: External validation of prostate cancer risk calculators in men undergoing mpMRI and transperineal biopsy
por: Wei, G., et al.
Publicado: (2021)

Non-timely clinically applicable ADC ratio in prostate mpMRI: a comparison with fusion biopsy results
por: Falaschi, Zeno, et al.
Publicado: (2022)

The combined value of mpUS and mpMRI-TRUS fusion for the diagnosis of clinically significant prostate cancer
por: Zhang, Xin, et al.
Publicado: (2022)

The impact of a second MRI and re-biopsy in patients with initial negative mpMRI-targeted and systematic biopsy for PIRADS ≥ 3 lesions
por: Zattoni, Fabio, et al.
Publicado: (2023)

Incorporating mpMRI biopsy data into established pre-RP nomograms: potential impact of an increasingly common clinical scenario
por: Leong, Joon Yau, et al.
Publicado: (2019)

Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI
por: Campistol, Miriam, et al.
Publicado: (2022)

Comparison of (68)Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer
por: Zhang, Qing, et al.
Publicado: (2017)

Pearls and pitfalls in diagnosing prostate cancer using multiparametric MRI (mpMRI)
por: Joshi, JJ, et al.
Publicado: (2015)

Optimising preoperative risk stratification tools for prostate cancer using mpMRI
por: Reisæter, Lars A. R., et al.
Publicado: (2017)

Differential diagnosis of uncommon prostate diseases: combining mpMRI and clinical information
por: Han, Chao, et al.
Publicado: (2021)

The comparative effectiveness of mpMRI and MRI-guided biopsy vs regular biopsy in a population-based PSA testing: a modeling study
por: Getaneh, Abraham M., et al.
Publicado: (2021)

Focal Irreversible Electroporation for Localized Prostate Cancer – Oncological and Safety Outcomes Using mpMRI and Transperineal Biopsy Follow-Up
por: Gielchinsky, Ilan, et al.
Publicado: (2023)

Histopathology-validated lesion detection rates of clinically significant prostate cancer with mpMRI, [(68)Ga]PSMA-11-PET and [(11)C]Acetate-PET
por: Sandgren, Kristina, et al.
Publicado: (2023)

(68)Ga-PSMA-PET/CT in addition to mpMRI in men undergoing biopsy during active surveillance for low- to intermediate-risk prostate cancer: study protocol for a prospective cross-sectional study
por: Gondoputro, William, et al.
Publicado: (2023)

Applications of Artificial Intelligence to Prostate Multiparametric MRI (mpMRI): Current and Emerging Trends
por: Bardis, Michelle D., et al.
Publicado: (2020)

bpMRI and mpMRI for detecting prostate cancer: A retrospective cohort study
por: Pan, Yongsheng, et al.
Publicado: (2023)

AI-predicted mpMRI image features for the prediction of clinically significant prostate cancer
por: Li, Song, et al.
Publicado: (2023)

Performance of prostate health index and PSA density in a diverse biopsy‐naïve cohort with mpMRI for detecting significant prostate cancer
por: Carbunaru, Samuel, et al.
Publicado: (2021)

Intraindividual comparison between (68)Ga-PSMA-PET/CT and mpMRI for intraprostatic tumor delineation in patients with primary prostate cancer: a retrospective analysis in 101 patients
por: Spohn, Simon, et al.
Publicado: (2020)

Dynamic Contrast-Enhanced Study in the mpMRI of the Prostate—Unnecessary or Underutilised? A Narrative Review
por: Guljaš, Silva, et al.
Publicado: (2023)

Transrectal ultrasound examination of prostate cancer guided by fusion imaging of multiparametric MRI and TRUS: avoiding unnecessary mpMRI-guided targeted biopsy
por: Xu, Guang, et al.
Publicado: (2022)

Prostate Cancer Detection with mpMRI According to PI-RADS v2 Compared with Systematic MRI/TRUS-Fusion Biopsy: A Prospective Study
por: Sauck, Anja, et al.
Publicado: (2022)

Evaluation of the PI-RADS Scoring System for Classifying mpMRI Findings in Men with Suspicion of Prostate Cancer
por: Junker, Daniel, et al.
Publicado: (2013)

Transrectal Ultrasound in Prostate Cancer: Current Utilization, Integration with mpMRI, HIFU and Other Emerging Applications
por: Panzone, John, et al.
Publicado: (2022)

Targeted 11C–choline PET-CT/TRUS software fusion-guided prostate biopsy in men with persistently elevated PSA and negative mpMRI after previous negative biopsy
por: Lazzeri, Massimo, et al.
Publicado: (2017)

Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men
por: Hendriks, Rianne J., et al.
Publicado: (2021)

Developing a predictive model for clinically significant prostate cancer by combining age, PSA density, and mpMRI
por: Ma, Zengni, et al.
Publicado: (2023)

Microvascular proliferation is associated with high tumour blood flow by mpMRI and disease progression in primary prostate cancer
por: Børretzen, Astrid, et al.
Publicado: (2023)

Exploring the efficacy of multi-flavored feature extraction with radiomics and deep features for prostate cancer grading on mpMRI
por: Khanfari, Hasan, et al.
Publicado: (2023)

Do cancer detection rates differ between transperineal and transrectal micro-ultrasound mpMRI-fusion-targeted prostate biopsies? A propensity score-matched study
por: Rakauskas, Arnas, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a70umrrhmotp8jagr1ddt7vu88